Status:
UNKNOWN
A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection
Lead Sponsor:
Samsung Medical Center
Conditions:
Gastric Cancer
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if reduced port totally laparoscopic distal gastrectomy with complete D2 lymph node dissection for gastric cancer is safe and oncological feasible. 67 patien...
Eligibility Criteria
Inclusion
- histologically confirmed adenocarcinoma of the stomach
- Eastern Cooperative Oncology Group Eastern Cooperative Oncology Group performance status 0-1,
- signed informed consent
- location of the primary tumor in the antrum, angle and lower body
- no evidence of distant metastasis or invasion to adjacent organs or serosal infiltration
Exclusion
- metastatic disease
- previous history of malignancy in any organ
- any co-morbidity obviating major surgery
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2015
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT02311595
Start Date
December 1 2014
End Date
March 1 2015
Last Update
December 8 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.